.png){kind=icon}
.png){kind=icon}
Return
The role of disease-modifying anti-rheumatic drugs (DMARDs) in cardiovascular risk management induced by rheumatoid arthritis
.png){kind=icon}
PRE
AI
Y
N
C
X
J
P
P
X
Y
H
D
W
Z
H
DOI：10.1016/j.yexcr.2026.115040.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Rheumatoid arthritis (RA) significantly increases cardiovascular disease (CVD) risks. • RA-associated cardiovascular risks are driven by four interconnected mechanisms, including chronic immune-inflammatory activation; metabolic dysregulation and oxidative stress; genetic and epigenetic regulation; and the dual effects of long-term drug therapy. • Disease-modifying anti-rheumatic drugs (DMARDs) critically improve cardiovascular risks induced by RA. • The potential role of cell therapy in cardiovascular risk management induced by RA also is discussed.
Keywords:
rheumatoid arthritis
cardiovascular disease
disease-modifying anti-rheumatic drugs
inflammation
oxidative stress
Journal
IF:
3.5
Papers:
1.1W
Citations:
2.0W
Organization
Cited Papers